CSL Behring snaps up a close­ly-held biotech part­ner and its IL-6 drug — for trans­plant re­jec­tion

Hav­ing close­ly watched and fund­ed a Cana­di­an biotech part­ner’s IL-6 drug for two and a half years, CSL Behring is snap­ping it all up.

The buy­out of Vi­taeris ar­rives as IL-6 — a proin­flam­ma­to­ry in­ter­leukin typ­i­cal­ly as­so­ci­at­ed with arthri­tis — has gar­nered in­ter­est as a po­ten­tial cul­prit for the acute res­pi­ra­to­ry dis­tress syn­drome that plagues cer­tain Covid-19 pa­tients. CSL, though, says it’s still dri­ven by the an­ti­body’s po­ten­tial for kid­ney trans­plant re­jec­tion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN